Piper Sandler analyst Allison Bratzel maintained a Hold rating on Humacyte (HUMA – Research Report) today and set a price target of $4.00. The company’s shares closed yesterday at $3.14.
Bratzel covers the Healthcare sector, focusing on stocks such as Codexis, Incyte, and Ionis Pharmaceuticals. According to TipRanks, Bratzel has an average return of 11.0% and a 60.00% success rate on recommended stocks.
Humacyte has an analyst consensus of Strong Buy, with a price target consensus of $8.00.
Based on Humacyte’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $26 million. In comparison, last year the company earned a revenue of $31 thousand and had a GAAP net loss of $25.28 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Humacyte (HUMA) Company Description:
Alpha Healthcare Acquisition Corp is a blank check company.
Read More on HUMA:
- Options Volatility and Implied Earnings Moves Today, March 22, 2024
- Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
- Humacyte reports Q4 EPS (24c), consensus (24c)
- HUMA Upcoming Earnings Report: What to Expect?
- Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024
